Next generation sequencing demonstrates association between tumor suppressor gene aberrations and poor outcome in patients with cancer

P53 Mutations in Advanced Cancers: Clinical Characteristics, Outcomes, and Correlation between Progression-Free Survival and Bevacizumab-Containing Therapy

(2015) Rabih Said et al.   Oncotarget

Unique molecular signatures as a hallmark of patients with metastatic breast cancer: Implications for current treatment paradigms

(2015) Jennifer J. Wheler et al.   Oncotarget

Genetic inhibition of the atypical kinase Wee1 selectively drives apoptosis of p53 inactive tumor cells

(2014) William N Pappano et al.   BMC CANCER

Inactivation of the CDKN2A Tumor-Suppressor Gene by Deletion or Methylation Is Common at Diagnosis in Follicular Lymphoma and Associated with Poor Clinical Outcome

(2014) A. Alhejaily et al.   CLINICAL CANCER RESEARCH

Exploiting APC Function as a Novel Cancer Therapy

(2014) Alyssa Lesko et al.   CURRENT DRUG TARGETS

Therapeutic Targeting of Cancers with Loss of PTEN Function

(2014) Lloye Dillon et al.   CURRENT DRUG TARGETS

Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs

(2014) Mark G. Kris et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Molecular Tumor Board: The University of California San Diego Moores Cancer Center Experience

(2014) M. Schwaederle et al.   ONCOLOGIST

Assessing PIK3CA and PTEN in Early-Phase Trials with PI3K/AKT/mTOR Inhibitors

(2014) Filip Janku et al.   Cell Reports

The prognostic value of CDKN2A hypermethylation in colorectal cancer: a meta-analysis

(2013) X Xing et al.   BRITISH JOURNAL OF CANCER

Targeting ATR in DNA damage response and cancer therapeutics

(2013) Emmanouil Fokas et al.   CANCER TREATMENT REVIEWS

Biomarker-Directed Therapy of Squamous Carcinomas of the Head and Neck: Targeting PI3K/PTEN/mTOR Pathway

(2013) Floyd Christopher Holsinger et al.   JOURNAL OF CLINICAL ONCOLOGY

Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration

(2012) Douglas G Altman et al.   BMC Medicine

Outcomes of Phase II Clinical Trials with Single-Agent Therapies in Advanced/Metastatic Non-Small Cell Lung Cancer Published between 2000 and 2009

(2012) F. Janku et al.   CLINICAL CANCER RESEARCH

Personalized Medicine in a Phase I Clinical Trials Program: The MD Anderson Cancer Center Initiative

(2012) A.-M. Tsimberidou et al.   CLINICAL CANCER RESEARCH

Vandetanib is effective in EGFR-mutant lung cancer cells with PTEN deficiency

(2012) Hiromasa Takeda et al.   EXPERIMENTAL CELL RESEARCH

PI3K/AKT/mTOR Inhibitors in Patients With Breast and Gynecologic Malignancies HarboringPIK3CAMutations

(2012) Filip Janku et al.   JOURNAL OF CLINICAL ONCOLOGY

PIK3CA Mutations in Patients with Advanced Cancers Treated with PI3K/AKT/mTOR Axis Inhibitors

(2011) F. Janku et al.   MOLECULAR CANCER THERAPEUTICS

p53 mutation, deprivation and poor prognosis in primary breast cancer

(2010) L Baker et al.   BRITISH JOURNAL OF CANCER

Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus

(2010) Federica Di Nicolantonio et al.   JOURNAL OF CLINICAL INVESTIGATION

Pilot Study Using Molecular Profiling of Patients' Tumors to Find Potential Targets and Select Treatments for Their Refractory Cancers

(2010) Daniel D. Von Hoff et al.   JOURNAL OF CLINICAL ONCOLOGY

A practical guide to understanding Kaplan-Meier curves

(2010) Jason T. Rich et al.   OTOLARYNGOLOGY-HEAD AND NECK SURGERY

mTOR Complex 2 Is Required for the Development of Prostate Cancer Induced by Pten Loss in Mice

(2009) David A. Guertin et al.   CANCER CELL

Loss of Phosphatase and Tensin Homologue Deleted on Chromosome 10 Engages ErbB3 and Insulin-Like Growth Factor-I Receptor Signaling to Promote Antiestrogen Resistance in Breast Cancer

(2009) T. W. Miller et al.   CANCER RESEARCH

Loss of PTEN expression is associated with colorectal cancer liver metastasis and poor patient survival

(2008) Hirozumi Sawai et al.   BMC GASTROENTEROLOGY

The role of PTEN signaling perturbations in cancer and in targeted therapy

(2008) M Keniry et al.   ONCOGENE